CoChat

Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody

Open access
Garrido, Greta, Rabasa, Ailem, Sánchez, Belinda, López, María Victoria, Blanco, Rances, López, Armando, Hernández, Diana Rosa, Pérez, Rolando, Fernández, Luis Enrique · 2011 · The Journal of Immunology

The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.

Abstract

Despite promising results in the use of anti-epidermal growth factor receptor (EGFR) Abs for cancer therapy, several issues remain to be addressed. An increasing emphasis is being placed on immune effector mechanisms. It has become clear for other Abs directed to tumor targets that their effects involve the adaptive immunity, mainly by the contribution of Fc region-mediated mechanisms. Given the relevance of EGFR signaling for tumor biology, we wonder whether the oncogene inhibition could contribute to Ab-induced vaccine effect. In a mouse model in which 7A7 (an anti-murine EGFR Ab) and AG1478 (an EGFR-tyrosine kinase inhibitor) displayed potent antimetastatic activities, depletion experiments revealed that only in the case of the Ab, the effect was dependent on CD4(+) and CD8(+) T cells. Correspondingly, 7A7 administration elicited a remarkable tumor-specific CTL response in hosts. Importantly, experiments using 7A7 F(ab')(2) suggested that in vivo Ab-mediated EGFR blockade may play an important role in the linkage with adaptive immunity. Addressing the possible mechanism involved in this effect, we found quantitative and qualitative differences between 7A7 and AG1478-induced apoptosis. EGFR blocking by 7A7 not only prompted a higher proapoptotic effect on tumor metastases compared with AG1478, but also was able to induce apoptosis with immunogenic potential in an Fc-independent manner. As expected, 7A7 but not AG1478 stimulated exposure of danger signals on tumor cells. Subcutaneous injection of 7A7-treated tumor cells induced an antitumor immune response. This is the first report, to our knowledge, of a tumor-specific CTL response generated by Ab-mediated EGFR inhibition, suggesting an important contribution of immunogenic apoptosis to this effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1003477

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Baselga, J., R. Herbst, P. LoRusso, D. Rischin, M. Ranson, R. Plummer, E. Raymond, A.-M. Maddox, S. Kaye, D. Kieback, et al. 2000. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor re- ceptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tu- mor types: evidence of activity and good tolerability. Proc. Am. Soc. Clin. Oncol. 19: 2000.
  2. Liu, B., M. Fang, M. Schmidt, Y. Lu, J. Mendelsohn, and Z. Fan. 2000. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br. J. Cancer 82: 1991-1999.

Cited by

See all 91

Metadata

Authors
Garrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E.
Affiliations
  • Center of Molecular Immunology (Cuba) (CU)
  • Quality Control Department, Quality Direction, Center of Molecular Immunology , Havana 11600 ,
  • Tumor Immunology Direction, Molecular Immunology Institute, Center of Molecular Immunology , Havana 11600 ,
  • Innovative Direction, Molecular Immunology Institute, Center of Molecular Immunology , Havana 11600 ,
Corresponding author
  • Garrido, Greta
  • Rabasa, Ailem
Venue
The Journal of Immunology
Published
2011-11
Volume
187
Issue
10
Pages
4954-4966
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2144107170
Cited by
91
References
64
Citations by year
2026: 2 · 2025: 1 · 2023: 8 · 2022: 5 · 2021: 8 · 2020: 10 · 2019: 8 · 2018: 8 · 2017: 4 · 2016: 2 · 2015: 9 · 2014: 9 · 2013: 9 · 2012: 6
FWCI
3.66
Type
journal article
Language
en
Open access
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
epidermal growth factor receptor, anti-EGFR monoclonal antibody, AG1478, EGFR tyrosine kinase inhibitors, tumor-specific cytotoxic T lymphocytes, metastasis, adaptive immunity, damage-associated molecular patterns, antitumor immunity, CD4 and CD8 T cells
MeSH terms
Animals, Antibodies, Monoclonal, Antibody Specificity, Cells, Cultured, Female, Immunoglobulin Fc Fragments, Lung Neoplasms, Melanoma, Experimental, Mice, Inbred C57BL, T-Lymphocytes, Cytotoxic, Apoptosis, Carcinoma, Lewis Lung, Antibodies, Blocking, Cell Line, Tumor, Mice, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.